1. Drug-tolerant persister cancer cells are resistant to traditional therapies, and represent a reservoir from which drug-resistant tumors may emerge.
2. Researchers have identified GPX4 as a potential target for treating persister cells, as loss of GPX4 function results in selective death of these cells in vitro and prevents tumor relapse in vivo.
3. RNAseq and small-molecule screens were used to identify cellular processes that may be selectively dependent on GPX4 in persister cells.
The article is generally reliable and trustworthy, providing evidence for its claims through the use of RNAseq and small-molecule screens to identify cellular processes that may be selectively dependent on GPX4 in persister cells. The article also provides evidence for the efficacy of targeting GPX4 as a therapeutic strategy to prevent acquired drug resistance, with loss of GPX4 function resulting in selective death of these cells in vitro and preventing tumor relapse in vivo.
The article does not appear to contain any promotional content or partiality, nor does it present only one side of the argument without exploring counterarguments or missing points of consideration. It is also noted that possible risks associated with targeting GPX4 are mentioned, such as potential off-target effects or toxicity due to inhibition of other hydroperoxidases.
In conclusion, this article appears to be reliable and trustworthy, providing evidence for its claims while noting potential risks associated with targeting GPX4 as a therapeutic strategy.